Developed API’s : Anti-Osteoporotic


Raloxifene Hydrochloride

CAS NO. 82640-04-8
Therapeutic Class: Antiosteoporotic
Pharmacopoeia compliance: USP/Ph.Eur

Raloxifene hydrochloride is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density. Raloxifene has been found to be effective in the treatment of gynecomastia (male breast development) in adolescents or osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.

Raloxifene was first introduced, for the prevention of postmenopausal osteoporosis, in 1997. It was subsequently approved for the treatment of postmenopausal osteoporosis in 1999 and to reduce the risk of breast cancer in certain women in 2007. It is available as a generic medication